Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06282549 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06282549 · ClinicalTrials.gov record · last posted 2024-11-19

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

Name: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension — clinical trial record (NCT06282549)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhaseNot specified

SponsorYuhan Corporation

Started2022-06-08

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-02-20; most recent amendment 2024-11-14. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-11-12

Status change Recruiting→Active, Not Recruitingv1

Trial Details

NCT Number	NCT06282549
Lead Sponsor	Yuhan Corporation
Conditions	Essential Hypertension
Enrollment	1,219 participants
Start Date	2022-06-08
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-19